187 related articles for article (PubMed ID: 37209450)
1. Current scenario of pyrazole hybrids with in vivo therapeutic potential against cancers.
Xu Z; Zhuang Y; Chen Q
Eur J Med Chem; 2023 Sep; 257():115495. PubMed ID: 37209450
[TBL] [Abstract][Full Text] [Related]
2. Current development of pyrazole-azole hybrids with anticancer potential.
Zhang S; Ye Y; Zhang Q; Luo Y; Wang ZC; Wu YZ; Zhang XP; Yi C
Future Med Chem; 2023 Aug; 15(16):1527-1548. PubMed ID: 37610862
[TBL] [Abstract][Full Text] [Related]
3. Recent updates on 1,2,3-, 1,2,4-, and 1,3,5-triazine hybrids (2017-present): The anticancer activity, structure-activity relationships, and mechanisms of action.
Dong G; Jiang Y; Zhang F; Zhu F; Liu J; Xu Z
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200479. PubMed ID: 36372519
[TBL] [Abstract][Full Text] [Related]
4. Benzimidazole hybrids as anticancer drugs: An updated review on anticancer properties, structure-activity relationship, and mechanisms of action (2019-2021).
Feng LS; Su WQ; Cheng JB; Xiao T; Li HZ; Chen DA; Zhang ZL
Arch Pharm (Weinheim); 2022 Jun; 355(6):e2200051. PubMed ID: 35385159
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities.
Yang M; Liu H; Zhang Y; Wang X; Xu Z
Curr Top Med Chem; 2020; 20(16):1461-1467. PubMed ID: 31994464
[TBL] [Abstract][Full Text] [Related]
6. Isatin-azole hybrids and their anticancer activities.
Hou Y; Shang C; Wang H; Yun J
Arch Pharm (Weinheim); 2020 Jan; 353(1):e1900272. PubMed ID: 31691360
[TBL] [Abstract][Full Text] [Related]
7. The current scenario on anticancer activity of artemisinin metal complexes, hybrids, and dimers.
Zhang S; Yi C; Li WW; Luo Y; Wu YZ; Ling HB
Arch Pharm (Weinheim); 2022 Aug; 355(8):e2200086. PubMed ID: 35484335
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in the Development of Pyrazole Derivatives as Anticancer Agents.
Zhang Y; Wu C; Zhang N; Fan R; Ye Y; Xu J
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628906
[TBL] [Abstract][Full Text] [Related]
9. Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line.
Bennani FE; Doudach L; Cherrah Y; Ramli Y; Karrouchi K; Ansar M; Faouzi MEA
Bioorg Chem; 2020 Apr; 97():103470. PubMed ID: 32120072
[TBL] [Abstract][Full Text] [Related]
10. Current scenario of fused pyrimidines with in vivo anticancer therapeutic potential.
Xu Z; Wang L; Hu H
Arch Pharm (Weinheim); 2024 May; ():e202400202. PubMed ID: 38752780
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in isatin hybrids as potential anticancer agents.
Ding Z; Zhou M; Zeng C
Arch Pharm (Weinheim); 2020 Mar; 353(3):e1900367. PubMed ID: 31960987
[TBL] [Abstract][Full Text] [Related]
12. Heterocycles in Breast Cancer Treatment: The Use of Pyrazole Derivatives.
Ardevines S; Marqués-López E; Herrera RP
Curr Med Chem; 2023; 30(10):1145-1174. PubMed ID: 36043746
[TBL] [Abstract][Full Text] [Related]
13. Recent Updates on the Anticancer Activity of Quinoxaline Hybrids (Jan. 2017-Jan. 2022).
Feng LS; Gao C; Liu FW; Wang XP; Zhang ZL
Curr Top Med Chem; 2022; 22(17):1426-1441. PubMed ID: 36028933
[TBL] [Abstract][Full Text] [Related]
14. Current status of carbazole hybrids as anticancer agents.
Wang G; Sun S; Guo H
Eur J Med Chem; 2022 Feb; 229():113999. PubMed ID: 34838335
[TBL] [Abstract][Full Text] [Related]
15. Recent updates on 1,2,3-triazole-containing hybrids with in vivo therapeutic potential against cancers: A mini-review.
Zhao S; Liu J; Lv Z; Zhang G; Xu Z
Eur J Med Chem; 2023 May; 251():115254. PubMed ID: 36893627
[TBL] [Abstract][Full Text] [Related]
16. Recent Advancement in Drug Design and Discovery of Pyrazole Biomolecules as Cancer and Inflammation Therapeutics.
Alam MJ; Alam O; Naim MJ; Nawaz F; Manaithiya A; Imran M; Thabet HK; Alshehri S; Ghoneim MM; Alam P; Shakeel F
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557840
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Biological Evaluation of Novel Thiazolyl Substituted Bis-pyrazole Oxime Derivatives with Potent Antitumor Activities by Selectively Inducing Apoptosis and ROS in Cancer Cells.
Xiong B; Chen S; Zhu P; Huang M; Gao W; Zhu R; Qian J; Peng Y; Zhang Y; Dai H; Ling Y
Med Chem; 2019; 15(7):743-754. PubMed ID: 30147012
[TBL] [Abstract][Full Text] [Related]
18. The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies.
Nitulescu GM; Stancov G; Seremet OC; Nitulescu G; Mihai DP; Duta-Bratu CG; Barbuceanu SF; Olaru OT
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513232
[TBL] [Abstract][Full Text] [Related]
19. Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure-activity relationship.
Gao F; Huang G; Xiao J
Med Res Rev; 2020 Sep; 40(5):2049-2084. PubMed ID: 32525247
[TBL] [Abstract][Full Text] [Related]
20. Coumarin-containing hybrids and their anticancer activities.
Zhang L; Xu Z
Eur J Med Chem; 2019 Nov; 181():111587. PubMed ID: 31404864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
